Compare BIO-TECHNE Corp (TECH) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Ulta Beauty Inc — how do they compare? BIO-TECHNE Corp trades at $72.18 (market cap $11.24B), while Ulta Beauty Inc trades at $543.91 (market cap $23.59B). The key difference: Ulta Beauty Inc is far larger — about 2.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| TECH | ULTA | |
|---|---|---|
Market Cap | $11.24B | $23.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.29 | $706.82 |
52-Week Low | $43.31 | $450.75 |
Enterprise Value | $11.32B | $25.67B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
ULTA stock trades at $565.15, up 4.89% in the last session, with a bullish technical outlook supported by moving averages and strong support at $547. The company reported Q1 2026 EPS of $7.74, beating estimates, but faces margin compression with net income margin declining to 10.63% in 2025. Recent news highlights the end of its Target partnership as a potential growth opportunity, per BofA analysis on July 29, 2026.
The stock offers upside to the consensus price target of $618.29, with 57% of analysts rating it a buy, but risks include competitive pressures and volatile cash flows, with net cash flow turning negative in 2025. Investors should weigh robust ROE of 47.45% against elevated P/B of 9.41 and RSI levels suggesting overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
